The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates  by Choe, Hyeryun et al.
Cell, Vol. 85, 1135–1148, June 28, 1996, Copyright 1996 by Cell Press
The b-Chemokine Receptors CCR3 and CCR5
Facilitate Infection by Primary HIV-1 Isolates
Hyeryun Choe,*# Michael Farzan,*# Ying Sun,* HIV-1 infects T lymphocytes, monocytes/macro-
phages, dendritic cells and, in the central nervous sys-Nancy Sullivan,*† Barrett Rollins,§ Paul D. Ponath,‡
tem, microglia (Gartner et al., 1986; Koenig et al., 1986;Lijun Wu,‡ Charles R. Mackay,‡ Gregory LaRosa,‡
Pope et al., 1994; Weissman et al., 1995). All of theseWalter Newman,‡ Norma Gerard,‖ Craig Gerard,‖
cells express the CD4 glycoprotein, which serves asand Joseph Sodroski*†
the receptor for HIV-1 and HIV-2 (Dalgleish et al., 1984;*Division of Human Retrovirology
Klatzmann et al., 1984; Maddon et al., 1986). EfficientDana-Farber Cancer Institute
entry of HIV-1 into target cells is dependent upon bindingDepartment of Pathology
of the viral exterior envelope glycoprotein, gp120, toHarvard Medical School
the CD4-amino-terminal domain (McDougal et al., 1986;Boston, Massachusetts 02115
Helseth et al., 1990). After virus binding, the HIV-1 enve-†Department of Cancer Biology
lope glycoproteins mediate the fusion of viral and hostHarvard School of Public Health
cell membranes to completethe entry process (KowalskiBoston, Massachusetts 02115
et al., 1987; Stein et al., 1987; Helseth et al., 1990).‡LeukoSite, Inc.
Membrane fusion directed by HIV-1 envelope glycopro-215 First Street
teins expressed on the infected cell surface leads toCambridge, Massachusetts 02142
fusion with uninfected CD4-positive cells, resulting in§Department of Medicine
syncytia (Lifson et al., 1986; Sodroski et al., 1986).Dana-Farber Cancer Institute
Host cell factors in addition to CD4 have been sug-Harvard Medical School
gested to determine the efficiency of HIV-1 envelopeBoston, Massachusetts 02115
glycoprotein-mediated membrane fusion. Some human‖Perlmutter Laboratory
and animal cells were shown to be resistant to HIV-1
Children’s Hospital
infection and syncytium formation even when human
Department of Medicine
CD4 was expressed on the cell surface (Maddon et al.,
Department of Pediatrics 1986; Ashorn et al., 1990; Chesebro et al., 1990;
Beth Israel Hospital McKnight et al., 1994). Experiments with somatic cell
Harvard Medical School hybrids suggested the possibility that a positive factor
Boston, Massachusetts 02115 expressed in cells susceptible to syncytium formation
could complement the block to fusion in resistant cell
types (Clapham et al., 1991; Dragic et al., 1992; Broder et
Summary al., 1993). HIV-1 variantsexhibiting distinct differences in
the ability to fuse with and to enter particular subsets
of CD4-positive cells have been identified (Broder andWe examined the ability of chemokine receptors and
Berger, 1995). All primary, clinical HIV-1 isolates, definedrelated G protein–coupled receptors to facilitate infec-
as viruses that have not been passaged on immortalizedtion by primary, clinical HIV-1 isolates. CCR5, when
cell lines, replicate in primary monocytes/macrophagesexpressed along with CD4, theHIV-1 receptor, allowed
and in primary T lymphocytes. Two groups of primarycell lines resistant to most primary HIV-1 isolates to
HIV-1 isolates have been defined, based on replicationbe infected. CCR3 facilitated infection by a more re-
rate in peripheral blood mononuclear cells (PBMC) andstricted subset of primary viruses, and binding of the
the ability to infect and induce the formation of syncytiaCCR3 ligand, eotaxin, inhibited infection by these iso-
in immortalized CD4-positive cell lines (A˚sjo¨ et al., 1986;lates. Utilization of CCR3 and CCR5 on the target cell
Cheng-Mayer et al., 1988; Fenyo¨ et al., 1988; Tersmettedepended upon the sequence of the third variable (V3)
et al., 1988). Most primary HIV-1 viruses that initiateregion of the HIV-1 gp120 exterior envelope glycopro-
human infection and that persist throughout the coursetein. The ability of various members of the chemokine
of infection replicate to low levels in PBMC and do notreceptor family to support the early stages of HIV-1
replicate in immortalized T cell lines (A˚sjo¨ et al., 1986;infection helps to explain viral tropism and b-chemo-
Schuitemaker et al., 1991, 1992; Connor et al., 1993;kine inhibition of primary HIV-1 isolates.
Connor and Ho, 1994a, 1994b). These viruses are re-
ferred to herein as macrophage-tropic primary isolates.
In someHIV-1-infected individuals, viruses that replicate
Introduction to higher levels in PBMC and that can infect and induce
the formation of syncytia in immortalized CD4-positive
Human immunodeficiency viruses type 1 and type 2 cell lines emerge late in the course of infection (A˚sjo¨ et
(HIV-1 and HIV-2) are the etiologic agents of acquired al., 1986; Schuitemaker et al., 1992; Connor et al., 1993;
immunodeficiency syndrome (AIDS) in humans (Barre´- Connor and Ho, 1994a, 1994b). These viruses will be
Sinoussi et al., 1983; Gallo et al., 1984). AIDS results referred to herein as T cell line–tropic primary viruses.
from the depletion of CD4-positive T lymphocytes in The T cell line–tropic primary viruses, by virtue of their
HIV-infected individuals (Fauci et al., 1984). ability to replicate in some immortalized cell lines, serve
as precursors to the laboratory-adapted isolates, which
have been extensively passaged on such cell lines. Lab-#The first two authors contributed equally to the work reported in
this paper. oratory adaptation results in a loss of the ability of HIV-1
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to replicate in primary monocyte/macrophage cultures The large family of G protein–coupled receptors re-
sponds to chemoattractants, neurotransmitters, pep-(Chesebro et al., 1991; Schuitemaker et al., 1991; West-
ervelt et al., 1992; Valentin et al., 1994). Thus, while all tide hormones, light, and odorants. Amino acid identity
among receptors that bind functionally related ligandsHIV-1 isolates replicate in primary T lymphocytes, three
groups of virus variants can be defined based on the ranges from 20%–80% (Probst et al., 1992; Gerard and
Gerard, 1994). Seven transmembrane receptors thatability to replicate in primary monocyte/macrophages
or in immortalized T cell lines. The macrophage-tropic transduce their signals through heterotrimeric G pro-
teins are used by leukocytes to respond to chemokinesprimary viruses cannot infect T cell lines, laboratory-
adapted viruses cannot infect primary monocytes/mac- (Horuk, 1994). Chemokines are a family of structurally
related peptides that recruit leukocytes to inflammatoryrophages, and T cell line–tropic primary viruses exhibit
dual-tropism for these cell types. lesions, induce release of granule contents from granu-
locytes, regulate integrin avidity, and in general exhibitChanges in the viral envelope glycoproteins, in partic-
ular in the third variable (V3) region of the gp120 exterior proinflammatory properties. The a chemokines, or CXC
chemokines, primarily act upon neutrophils, while theenvelope glycoprotein, determine tropism-related phe-
notypes (Cheng-Mayer et al., 1990; O’Brien et al., 1990; b chemokines, or CC chemokines, generally act upon
monocytes, lymphocytes, basophils, and eosinophilsHwang et al., 1991; Westervelt et al., 1991, 1992; Chese-
bro et al., 1992; Willey et al., 1994). Amino acid changes (Baggiolini et al., 1994; Schall and Bacon, 1994). Thus,
the CC chemokine receptors potentially exhibit a tissuein the V3 region (Helseth et al., 1990; Freed et al., 1991;
Ivanoff et al., 1991; Bergeron et al., 1992; Grimaila et al., distribution consistent with the known tropism of HIV-1.
While there are a number of closely related molecules1992; Page et al., 1992; Travis et al., 1992) and the bind-
ing of antibodies to this domain (Putney et al., 1986; in the CC chemokine receptor family, five of these have
been characterized in ligand binding assays. These areGoudsmit et al., 1988; Linsley et al., 1988; Rusche et al.,
1988; Skinner et al., 1988; Javaherian et al., 1989) have designated CCR1, CCR2A, CCR2B, CCR3, CCR4, and
CCR5. (A uniform and simplified nomenclature for thebeen shown to disrupt a virus entry process other than
CD4 binding. The target cell dependence of the pheno- b-chemokine receptors is currently under discussion.
We utilize CCR as the contraction for CC chemokinetype resulting from V3 structural variation suggested
that the V3 region, which contains a surface-exposed, receptor. The subdesignations 1, 2A, 2B, 3, 4, and 5 are
those commonly used by investigators in the field.) Heredisulfide-linked loop (Leonard et al., 1990; Moore et al.,
1994), might act in conjunction with target cell moieties we examine the potential role of these and other related
receptors in the infection of cells by primary HIV-1 exhib-to determine the efficiency of membrane fusion events.
Recently, an “orphan” G protein–coupled seven- iting macrophage-tropic and T cell line–tropic pheno-
types.transmembrane-segment receptor, variously called
HUMSTSR, LCR-1, or LESTR (Federsppiel et al., 1993;
Jazin et al., 1993; Loetscher et al., 1994) has been shown
Resultsto allow a range of nonhuman, CD4-expressing cells to
support infection and cell fusion mediated by labora-
A Subset of Chemokine Receptors Facilitatestory-adapted HIV-1 envelope glycoproteins (Feng et al.,
Infection by Macrophage-Tropic HIV-11996). Feng et al. (1996) have suggested the name
To assess the efficiency with which HIV-1 viruses con-“fusin” for this protein, although a standardized nomen-
taining different envelope glycoproteins mediate earlyclature awaits identification of its natural function. Anti-
events in HIV-1 infection, an env-complementationbodies to HUMSTSR blocked cell fusion and infection
assay (Helseth et al., 1990; Thali et al., 1994) was utilized.by laboratory-adapted HIV-1 isolates but not by macro-
Recombinant HIV-1 viruses were produced by cotrans-phage-tropic primary viruses. While its natural ligand is
fection of HeLa cells with two plasmids, pHXBH10Denv-currently unknown, HUMSTSR exhibits sequence simi-
CAT and pSVIIIenv. The pHXBH10DenvCAT plasmidlarity to the receptor for interleukin-8, an a (CXC) chemo-
contains an HIV-1 provirus with a deletion in the envkine (Probst et al., 1992). It has also been observed that
gene and a replacement of the nef gene with a geneinfection of macrophage-tropic primary HIV-1 isolates,
encoding chloramphenicol acetyltransferase (CAT). Dif-but not that of a laboratory-adapted isolate, could be
ferent pSVIIIenv plasmids encoding the envelope glyco-inhibited by the b chemokines RANTES, MIP-1a, and
proteins derived from a laboratory-adapted HIV-1 iso-MIP-1b (Cocchi et al., 1995). High endogenous expres-
late (HXBc2) and from macrophage-tropic primary HIV-1sion of these b chemokines has been suggested to ac-
isolates (Br20-4, ADA, and YU2) were used. The recom-count for the in vitro resistance to HIV-1 infection of
binant viruses produced in the HeLa supernatants thusCD4-positive T cells from uninfected individuals with
contain different envelope glycoproteins, allowing anmultiple sexual exposures to seropositive partners (Pax-
assessment of the ability of these glycoproteins to medi-ton et al.,1996). This resistance was only seen for macro-
ate a single round of infection. Control viruses lackingphage-tropic and not T cell line–tropic viruses and was
envelope glycoproteins were produced by transfectinginfluenced by the structure of the third variable (V3)
HeLa cells with the pHXBH10DenvCAT plasmid alone.gp120 region of the infecting virus. The available data
An equal number of reverse transcriptase units of thesuggest that at least one other host cell surface mole-
recombinant viruses in the HeLa supernatants was incu-cule besides CD4 and distinct from HUMSTSR facilitates
bated with target cells. HeLa cells transfected with plas-the entry of primary, macrophage-tropic HIV-1 isolates,
mids expressing human CD4 and various seven-trans-and that this moleculemight be influenced by interaction
with b chemokines. membrane-segment receptors were used as target
b-Chemokine Receptors as Entry Cofactors for HIV-1
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cells. The efficiency of the early phase of virus infection
was assessed by measurement of CAT activity in the
HeLa target cells 60 hr following infection.
Expression of human CD4 in HeLa cells was sufficient
for efficient infection of these cells by a recombinant
virus containing the laboratory-adapted HXBc2 enve-
lopeglycoproteins (Figure 1; Table 1), as previously pub-
lished (Brand et al., 1995). By contrast, infection of HeLa
cells expressing CD4 by viruses with the macrophage-
tropic ADA, YU2, and Br20-4 envelope glycoproteins
was inefficient. Other studies have demonstrated that
recombinant viruses with these envelope glycoproteins
are able to infect human PBMC (Westervelt et al., 1991;
Sullivan et al., 1995; Karlsson et al., 1996). These results
are consistent with previous observations suggesting
that macrophage-tropic primary HIV-1 isolates enter
most immortalized cells inefficiently (Cheng-Mayer et
al., 1988; Chesebro et al., 1991; Schuitemaker et al.,
1991).
Plasmids expressing the cDNAs of a number of che-
mokine receptors and related molecules were cotrans-
fected with the CD4-expressing plasmid into the HeLa
cells. The level of CD4 expression on the surface of the
HeLa cells was not affected by coexpression of the
chemokine receptors examined (data not shown). As
shown in Table 1, the expression of most of the seven-
transmembrane receptors did not affect infection by
the recombinant HIV-1 viruses. Expression of the CCR5
molecule resulted in significant enhancement of infec-
tion by viruses with the ADA, YU2, and Br20-4 envelope
glycoproteins, but had no effect on infection by the virus
containing the HXBc2 envelope glycoproteins (Figure 1;
Table 1). Expression of the CCR3 molecule also resulted
in enhanced infection by the viruses with ADA and YU2
envelope glycoproteins. The magnitude of this effect (9-
to 32-fold) was smaller than that seen for CCR5 (35- to
45-fold). CCR3 did not stimulate infection by the viruses
with BR20-4 and HXBc2 envelope glycoproteins. The
enhancing effects of CCR3 and CCR5 expression were
not seen when human CD4 was not expressed in the
HeLa target cells (Table 1).
To examine whether the level of expression of the
chemokine receptors on the surface of the transfected
HeLa cells might have influenced the results, fluores-
cence-activated cell sorter (FACS) analysis was used
to verify the expression of a subset of the chemokine
receptors (Table 1, legend). FACS analysis with a CCR3-
directed monoclonal antibody revealed that cell surface
expression of the wild-type CCR3 protein was inefficient
(data not shown). This is consistent with previous at-
tempts to express CCR3 in the context of a heterologous
cell (Daugherty et al., 1996; Ponath et al., 1996b). To
compare cell surface expression of CCR1, CCR3, and
CCR5 directly, the CCR1F, CCR3F, and CCR5F proteins,
Figure 1. CAT Activity in Transfected HeLa Cells Exposed to Re-which have identical amino-terminal epitope tags (Kunz
combinant HIV-1 Viruseset al., 1991), were studied. The presence of the epitope
HeLa cells expressing human CD4 and CD2 (A), CD4 and CCR1Ftag on the CCR3F and CCR5F molecules only minimally
(B), CD4 and CCR3 (C), or CD4 and CCR5 (D) were exposed toaffected the observed enhancement of infection by the
recombinant viruses containing either no envelope glycoproteins
primary viruses (Table 1). Cell surface levels of CCR3F (None) or envelope glycoproteins of the ADA, Br20-4, YU2, or HXBc2
and CCR5F were approximately 83- and 24-fold lower, isolates. The results of the CAT assay performed on the HeLa cell
respectively, than that of CCR1F in the transfected HeLa lysates are shown.
cells, when background fluorescence was taken into
account (Table 1, legend). Thus, the enhancement of
Cell
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Table 1. CAT Activity in Transfected HeLa Cells Infected with Recombinant HIV-1
HIV-1 Envelope Glycoproteins
Molecules Expressed in Target Cells None ADA YU2 Br20-4 HXBc2
CD4 (1CD2 control) 0.29 1.5 1.1 0.79 53.5
CD4 1 CCR1 ND 1.3 1.1 0.79 ND
CD4 1 CCR1F 0.25 2.0 2.0 1.1 51.9
CD4 1 CCR1F (sodium butyrate) ND ND 2.0 ND ND
CD4 1 CCR2 0.30 2.1 1.7 0.85 54.2
CD4 1 CCR3 0.25 14.2 35.0 1.2 53.1
CCR3 ND 1.5 0.61 1.2 ND
CD4 1 CCR3F 0.20 13.7 17.8 1.6 54.1
CD4 1 CCR3F (sodium butyrate) ND ND 32.7 ND ND
CD4 1 CCR4F ND 1.1 1.5 0.67 ND
CD4 1 CCR5 0.17 52.4 49.0 25.3 53.6
CCR5 ND 1.3 0.71 1.3 ND
CD4 1 CCR5F 0.20 61.9 51.0 39.8 53.4
CD4 1 CCR5F (sodium butyrate) ND ND 81.9 ND ND
CD4 1 IL8RA 0.28 1.5 0.84 0.64 57.0
CD4 1 IL8RB 0.41 1.9 1.3 0.64 55.1
CD4 1 HUMSTSR 0.19 1.1 0.68 0.45 53.0
CD4 1 Duffy antigen 0.08 0.41 0.33 0.22 53.4
CD4 1 EBI-1 ND 0.56 0.85 0.37 ND
CD4 1 PAF-RF ND 0.92 0.37 0.79 ND
CD4 1 FMLP-RF ND 2.0 1.0 2.3 ND
CD4 1 C5aR ND 0.66 0.73 0.45 ND
HeLa target cells expressing the molecules shown were infected with recombinant HIV-1 viruses containing the envelope glycoproteins listed.
In some of the experiments, the transfected HeLa target cells were treated with sodium butyrate prior to infection. CAT activity (percentage
conversion of chloramphenicol to acetylated forms per unit of lysate) was determined. The values reported represent the mean value from
duplicate experiments; standard deviation was less than 25% of the mean values. ND 5 not determined. The surface expression of the CCR2,
CCR3, IL8RA, IL8RB, and PAF-RF proteins was documented by FACS using specific monoclonal antibodies. The mean fluorescence intensities
observed were as follows: background, 6.8; CCR2, 60.6; IL8RA, 425.9; IL8RB, 132.8; and PAF-RF, 26.3. The surface expression of the CCR1F,
CCR3F, CCR4F, and CCR5F proteins was directly compared by using a monoclonal antibody reactive with the epitope tag (FLAG tag) on the
amino terminus of each of these molecules. The mean fluorescence intensities observed were as follows: background, 9.9; CCR1F, 233.8;
CCR3F, 12.6; CCR4F, 16.0; and CCR5F, 19.3. The mean fluorescence intensities observed for CCR1F and CCR3F following sodium butyrate
treatment were 332.0 and 15.1, respectively. Background values were obtained by using only the secondary antibody (FITC-conjugated anti-
mouse IgG) in the FACS analysis.
primary virus infection by CCR3 and CCR5 appears to ruses with primary, macrophage-tropic envelope glyco-
proteins.be specific and is not merely a result of higher surface
expression of these receptors.
We wished to examine whether increasing the cell
surface level of CCR3 and CCR5 might increase the Infection by Diverse HIV-1 Is Enhanced by CCR5
All of the envelope glycoproteins used in the experi-magnitude of the observed enhancement of infection.
Prior to virus infection, transfected HeLa cells were incu- ments described above were derived from HIV-1 viruses
from phylogenetic clade B (Myers et al., 1994). To exam-bated with sodium butyrate, which has been shown to
enhance the transcriptional activity of the cytomegalovi- ine the generality of the observed enhancement, HeLa
cells transiently expressing CD4 and either CD2, CCR1F,rus immediate early promoter used for chemokine re-
ceptor expression on the pcDNA3 plasmid (Palermo et CCR3, or CCR5 were incubated with recombinant vi-
ruses containing envelope glycoproteins from a geo-al., 1991). FACS analysis indicated that sodium butyrate
treatment increased the surface level of CCR1F and graphically diverse set of primary HIV-1 isolates (Gao et
al., 1996; Karlsson et al., 1996). The results, shown inCCR3F expression by approximately 1.5- to 1.9-fold,
when background fluorescence was taken into account Table 2, indicate that CCR5 was able to enhance the
infection of a broader array of viruses than was CCR3.(Table 1, legend). In cells expressing CCR3F and CCR5F,
an increase in the level of infection by the virus with the The infection of all of the primary viruses was increased
in cells expressing CD4 and CCR5 relative to that seenYU2 envelope glycoproteins resulted, whereas sodium
butyrate treatment had noeffect on infection bya control in cells expressing CD4 and CD2 or CD4 and CCR1F.
Of the panel of viruses tested, only those containingrecombinant virus containing the amphotropic murine
leukemia virus (A-MuLV) envelope glycoproteins (Table the ADA and YU2 envelope glycoproteins infected HeLa
cells expressing CD4 and CCR3 more efficiently than1 and data not shown). Sodium butyrate treatment of
HeLa cells transfected with plasmids expressing CD4 HeLa cells expressing CD4 and CD2. Recombinant vi-
ruses containing laboratory-adapted (HXBc2) viral enve-and CCR1F did not affect infection by the YU2 recombi-
nant virus. The results indicate that thecell surface levels lope glycoproteins did not infect HeLa cells expressing
CD4 and either CCR3 or CCR5 more efficiently than theyof CCR3 and CCR5 expression are limiting the magni-
tude of the observed enhancement of infection by vi- infected control cells expressing CD4 and CD2 or CD4
b-Chemokine Receptors as Entry Cofactors for HIV-1
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Table 2. CAT Activity in Transfected HeLa Cells Infected with Diverse Recombinant HIV-1
Envelope Glycoproteins
Molecules Expressed in
Target Cells None ADA YU2 BR20-4 Br25-9 Rw20-5 Th966 TN243 HXBc2 A-MuLV
CD4 (1CD2 control) 0.58 4.8 5.3 3.0 2.3 3.1 1.6 1.5 82.1 1742
CD4 1 CCR1F 0.33 5.7 5.0 3.6 3.5 8.4 1.4 2.5 131.7 1489
CD4 1 CCR3 0.35 45.9 70.5 3.0 5.0 5.4 1.3 1.5 111.3 1521
CD4 1 CCR5 0.36 102.3 103.9 49.8 11.6 70.4 16.7 16.6 104.9 812
HeLa cells expressing CD4 and chemokine receptors were incubated with recombinant viruses containing the designated envelope glycopro-
teins, and CAT activity measured. The ADA and YU2 envelope glycoproteins were derived from macrophage-tropic primary HIV-1 viruses
from North America (clade B). The Br20-4, Br25-9, Rw20-5, Th966, and TN243 envelope glycoproteins were derived from macrophage-tropic
primary HIV-1 viruses. The phylogenetic classification and geographic origin of these viruses are as follows: Br20-4 (clade B, Brazil), Br25-9
(clade C, Brazil), Rw20-5 (clade A, Rwanda), Th966 (clade E, Thailand), and TN243 (clade E, Thailand) (Gao et al., 1996; Karlsson et al., 1996).
The HXBc2 envelope glycoproteins were derived from a highly laboratory-adapted clade B HIV-1 isolate. The A-MuLV envelope glycoproteins
were derived from the amphotropic murine leukemia virus (Landau et al., 1991). The values reported represent mean CAT activity per unit of
cell lysate, as described in the Table 1 legend.
and CCR1F. Infection by control HIV-1 viruses pseu- expression on infection by the recombinant viruses used
in this study. Since most T cell line–tropic primary HIV-1dotyped with the amphotropic murine leukemia virus
(A-MuLV) envelope glycoproteins (Landau et al., 1991) isolates and laboratory-adapted isolates enter CD4-
positive HeLa cells efficiently (Chesebro et al., 1991),was not increased by the expression of CCR3 and CCR5
on the target cells. the use of the Cf2Th cells also allowed us to assess the
effect of chemokine receptor expression on infection by
these types of viruses. The results in Figure 3 indicateInhibition of CCR3-Dependent HIV-1
that none of the recombinant HIV-1 viruses containingInfection by Eotaxin
It has been reported that RANTES, MIP-1a, and MIP-
1b, the ligands for CCR5, inhibit the infection of primary
HIV-1 isolates (Cocchi et al., 1995; Paxton et al., 1996).
We wished to examine whether the binding of a ligand
toCCR3 would affect the ability of this chemokine recep-
tor to facilitate HIV-1 infection. HeLa-CD4 cells tran-
siently expressing CCR3 were incubated with eotaxin,
the major CCR3 ligand (Jose et al., 1994; Ponath et
al., 1996a), prior to infection by recombinant viruses
containing the YU2 or murine amphotropic (A-MuLV)
envelope glycoproteins. Additional control HeLa-CD4
cells expressing CD2, CCR1F, or CCR5 were included
in the assay. The data in Figure 2 indicate that eotaxin
exhibited a dose-dependent inhibition of infection of
HeLa-CD4 cells expressing CCR3 by YU2 recombinant
viruses. No effect of eotaxin was observed, even at high
concentrations, on infection by the recombinant virus
with the A-MuLV envelope glycoproteins. No effect of
eotaxin was observed on the infection of CCR5-express-
ing HeLa-CD4 cells by the YU2 recombinant virus. These
results indicate that, under circumstances where HIV-1
infection is dependent upon CCR3, eotaxin can inhibit
the efficiency of this process.
Chemokine Receptors Facilitate CD4-Dependent
HIV-1 Infection of Nonhuman Cells
To examine whether CCR3 and CCR5 expression could
facilitate HIV-1 infection of a nonhuman target cell,
Cf2Th canine thymocytes were transfected with a plas- Figure 2. Effect of Eotaxin on CCR3-Mediated Enhancement of YU2
Recombinant Virusmid expressing human CD4 in combination with a plas-
mid expressing either CD2, CCR3, or CCR5. A plasmid HeLa-CD4 cells transfected with plasmids expressing CD2, CCR1F,
CCR3, or CCR5 were incubated for 1 hr at 378C with increasingexpressing HUMSTSR, which has been reported to facil-
amounts of eotaxin.Recombinant HIV-1 viruses containing the enve-itate membrane fusion by laboratory-adapted HIV-1 iso-
lope glycoproteins of either the amphotropic murine leukemia viruslates (Feng et al., 1996), was also included in this experi-
(A-MuLV) or the YU2 macrophage-tropic primary isolate were added
ment. Since HUMSTSR is expressed at high levels in to the cells. CAT activity in the cell lysates was assessed 72 hr later.
HeLa cells (Feng et al., 1996), the use of different target The results of a single experiment, which was repeated with similar
results, are shown.cells allowed an examination of the effect of HUMSTSR
Cell
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the macrophage-tropic primary envelope glycoproteins
(ADA, YU2), T cell line–tropic primary envelope glycopro-
teins (89.6, ELI), or the laboratory-adapted (HXBc2) en-
velope glycoproteins efficiently infected Cf2Th cells ex-
pressing human CD4. A recombinant virus containing
the A-MuLV envelope glycoproteins was able to infect
the Cf2Th cells at a high level of efficiency. This was
expected since all of the Cf2Th cells in the culture were
potentially susceptible to infection by the virus with the
A-MuLV envelope glycoproteins. By contrast, only the
fraction of cells successfully transfected were poten-
tially infectible by the viruses with HIV-1 envelope glyco-
proteins. Expression of HUMSTSR in addition to CD4
facilitated infection by the HXBc2 and 89.6 recombinant
viruses but did not affect infection by viruses with the
ADA or YU2 envelope glycoproteins. A small positive
effect of HUMSTSR expression was seen on infection
by the ELI recombinant virus. These results are consis-
tent with a published report indicating that HUMSTSR
expression facilitated cell fusion directed by the enve-
lope glycoproteins of laboratory-adapted HIV-1 but not
of macrophage-tropic primary HIV-1 isolates (Feng et
al., 1996). The results also demonstrate that HUMSTSR
can be utilized by at least some T cell line–tropic primary
envelope glycoproteins to facilitate infection. Coexpres-
sion of CCR3 with human CD4 enhanced infection by the
ADA and YU2 recombinant viruses, with smaller positive
effects seen for the 89.6 and ELI recombinant viruses.
CCR3 expression did not affect the efficiency of infec-
tion by the virus with the HXBc2 envelope glycoproteins.
Infection of the CD4-expressing Cf2Th cells by the ADA,
YU2, and 89.6 recombinant viruses, but not by the ELI
and HXBc2 recombinant viruses, was enhanced by the
coexpression of CCR5. These results suggest that
HUMSTSR can be utilized by some T cell line–tropic
primary and laboratory-adapted HIV-1 isolates for infec-
tion and that CCR3 and CCR5 can be utilized by some T
cell line–tropic and macrophage-tropic primary isolates.
The results are summarized in Table 3.
HIV-1 Envelope Glycoprotein Determinants
of CCR3 and CCR5 Utilization
A major, although not the sole, determinant of viral tro-
pism is the primary structure of the third variable (V3)
region of the HIV-1 gp120 glycoprotein (Cheng-Mayer
et al., 1990; O’Brien et al., 1990; Hwang et al., 1991;
Westervelt et al., 1991; Chesebro et al., 1992; Willey et
al., 1994). To examine whether V3 structure influenced
sensitivity of HIV-1 to the presence of CCR3 and CCR5
on the target cell surface, HeLa-CD4 cells expressing
CCR3 or CCR5 were incubated with viruses containing
chimeric gp120 envelope glycoproteins. These chimeric
envelope glycoproteins are identical to that of the
Figure 3. Effect of CCR3, CCR5, and HUMSTSR Expression on HXBc2 laboratory-adapted isolate, except that the V3
HIV-1 Infection of Cf2Th Canine Thymocytes loop is derived from the ADA and YU2 macrophage-
Cf2Th canine thymocytes expressing human CD4 and CD2 (A), CD4 tropic primary isolates (Westervelt et al., 1992; Carrillo
and CCR3 (B), CD4 and CCR5 (C), or CD4 and HUMSTSR (D) were et al., 1993). The ADA and YU2 V3 domains have been
infectedwith recombinant viruses containing the indicated envelope
shown to confer on chimeric envelope glycoproteins theglycoproteins. The CAT assay results are shown.
ability to support HIV-1 infection of primary macro-
phages (Westervelt et al., 1992). Table 4 shows that
recombinant viruses containing the chimeric glycopro-
teins with the ADA and YU2 V3 loops, in contrast to those
b-Chemokine Receptors as Entry Cofactors for HIV-1
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Table 3. Properties of HIV-1 Envelope Glycoproteins Utilized in This Study
HIV-1 Envelope Syncytium Chemokine
Glycoproteins Classification Induction Passage History Receptor Utilization Reference
HXBc2 Laboratory- SI Extensive passage in HUMSTSR Fisher et al.,
Adapted T cell lines 1985
89.6 T cell line–tropic SI Homologous PBMC HUMSTSR, CCR5, Collman et al.,
primary CCR3 (low) 1992
ELI T cell line–tropic SI Homologous PBMC HUMSTSR (low), Alizon et al.,
primary CCR3 (low) 1986; Peden
et al., 1991
ADA Macrophage–tropic NSI Heterologous CCR3, CCR5 Gendelman et
primary primary al., 1988
macrophages
YU2 Macrophage–tropic NSI Unpassaged CCR3, CCR5 Li et al., 1991
primary
The ability of the molecularly cloned envelope glycoproteins used in this study to induce the formation of syncytia in immortalized T cell lines
is indicated. SI 5 syncytium-inducing, NSI 5 non-syncytium-inducing. The passage history of the virus prior to molecular cloning of the env
gene is indicated. The chemokine-receptor utilization is derived from the data in Figure 3.
containing the parental HXBc2 envelope glycoproteins, HeLa cells expressing the HXBc2 envelope glycopro-
teins formed syncytia with HeLa-CD4 cells (data notwere able to infect HeLa-CD4 cells more efficiently when
either CCR3 or CCR5 was expressed on the target cell. shown), consistent with the expression of endogenous
HUMSTSR in this cell line (Feng et al., 1996). The ADASubstitution of the YU2 V1/V2 variable loops into the
HXBc2 envelope glycoproteins did not increase the effi- and YU2 envelope glycoproteins, by contrast, did not
efficiently mediate the formation of syncytia with theciency of infection of HeLa-CD4 target cells expressing
CCR3 or CCR5, compared with the cells expressing CD4-positive HeLa cells expressing the CCR1 protein.
Syncytium formation directed by the chimeric HXBc2the CD2 control protein. These results indicate that the
structure of the gp120 V3 loop can influence the ability (ADA-V3) and HXBc2 (YU2-V3) envelope glycoproteins
was also inefficient with CCR1-expressing HeLa-CD4of HIV-1 viruses to respond to the presence of these
chemokine receptors in the target cells. target cells. Expression of CCR3 in addition to CD4 on
the HeLa cells resulted in syncytium formation directed
by the YU2 envelope glycoproteins. The expression of
CCR5 on the HeLa-CD4 cells allowed the formation ofCell–Cell Fusion Is Influenced by CCR3 and CCR5
Our results indicate that an envelope glycoprotein-spe- syncytia with cells expressing the ADA, YU2, and chime-
ric envelope glycoproteins. The number of syncytiacific process early in the HIV-1 life cycle is influenced
by the expression of CCR3 and CCR5 on the target cell. formed by the HXBc2 envelope glycoproteins was not
affected by CCR3 or CCR5 expression on the CD4-posi-To examine whether the membrane fusion process is
enhanced by the presence of these chemokine recep- tive HeLa cells (data not shown). Syncytium formation
in this assay was dependent upon gp120 binding totors, we utilized an assay measuring HIV-1 envelope
glycoprotein-mediated syncytium formation. In this CD4, since the OKT4a anti-CD4 monoclonal antibody,
which blocks gp120-CD4 interaction (McDougal et al.,assay, HeLa cells expressing different HIV-1 envelope
glycoproteins were cocultivated with either mock- 1986), inhibited the formation of syncytia. These results
indicate that expression of CCR3 and CCR5 on CD4-transfected HeLa-CD4 cells or HeLa-CD4 cells express-
ing CCR1, CCR3, or CCR5. Figure 4 shows that the positive target cells can enhance fusion events medi-
ated by macrophage-tropic primary virus envelope gly-number of syncytia observed when no envelope glyco-
proteins were expressed in the HeLa cells was minimal. coproteins. The results also indicate that the HIV-1
Table 4. CAT Activity in Transfected HeLa-CD4 Cells Infected with Recombinant Viruses Containing Chimeric HIV-1 Envelope
Glycoproteins
Envelope Glycoproteins
Molecules Expressed in HXBc2 HXBc2 HXBc2
HeLa-CD4 Target Cells ADA YU2 HXBc2 (ADA-V3) (YU2-V3) (YU2-V1/V2)
CD2 1.4 0.88 546 1.3 0.87 914
CCR3 19.0 73.4 542 40.8 5.9 1016
CCR5 ND ND 543 37.6 40.9 417
HeLa-CD4 cells expressing chemokine receptors were incubated with recombinant viruses containing wild-type or chimeric envelope glycopro-
teins, and CAT activity measured. The HXBc2 (ADA-V3) and HXBc2 (YU2-V3) envelope glycoproteins are identical to the HXBc2 envelope
glycoprotein except for a substitution of the ADA or YU2 V3 loop in the gp120 glycoprotein (Westervelt et al., 1992; Carillo et al., 1993). The
HXBc2 (YU2-V1/V2) chimeric envelope glycoprotein contains a substitution of the V1/V2 loops from the YU2 virus into the HXBc2 gp120
glycoprotein. ND 5 not determined. The values shown in the table are from a representative experiment, which was repeated with comparable
results.
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Figure 4. Effect of Chemokine Receptor Expression on HIV-1 Envelope Glycoprotein-Directed Syncytium Formation
HeLa cells expressing either no envelope glycoprotein (None) or the ADA, YU2, HXBc2 (ADA-V3), and HXBc2 (YU2-V3) envelope glycoproteins
were cocultivated with HeLa-CD4 expressing CCR1, CCR3, or CCR5. In one set of experiments, 2 mg/ml of the OKT4a antibody (Ortho
Pharmaceuticals, Inc.) was added at the beginning of the cocultivation. After 12 hr, the syncytia in the wells were counted. The results of a
single experiment are shown. The experiment was repeated with comparable results.
gp120 V3 loop sequence determines the ability of the (Daugherty et al., 1996; Kitaura et al., 1996; Ponath et
al., 1996b). The latter observation suggests that CCR3envelope glycoproteins to utilize CCR5 as a fusion co-
factor. could not be the sole factor facilitating the infection of
primary HIV-1 isolates, all of which replicate in PBMC.
While the involvement of CCR5 is likely to be relevantDiscussion
to a greater variety of HIV-1 target cells, CCR3 may
play an important role in a limited number of cell types.The results presented herein indicate that, in addition
to CD4, members of the chemokine receptor family play Eosinophils, which express high levels of CCR3 (Daugh-
erty et al., 1996; Kitaura et al., 1996; Ponath et al., 1996b),critical roles in early events in HIV-1 infection. The par-
ticular chemokine receptors utilized by HIV-1 variants also express CD4 and have been reported to be in-
fectible by HIV-1 (Freedman et al., 1991; Weller et al.,differ, depending upon previously characterized differ-
ences in target cell preference. The ability of laboratory- 1995). In one of these studies (Freedman et al., 1991),
two primary HIV-1 isolates, but not a laboratory-adaptedadapted HIV-1 viruses to replicate in immortalized CD4-
positive cell lines has been shown to involve an orphan virus, were able to replicate in bone marrow–derived
eosinophils. It is not known whether the ability of mono-receptor referred to as fusin, HUMSTSR, LESTR, or
LCR1 (Feng et al., 1996). Our results confirm the involve- cytes to respond to high concentrations of eotaxin (Po-
nath et al., 1996a) indicates a low level of expression ofment of HUMSTSR in infection by laboratory-adapted
HIV-1 and demonstrate a role for this molecule in infec- CCR3 on these cells, or the presence of another low
affinity receptor. MCP-3, one of the CCR3 ligands, is antion by some primary, T cell line–tropic HIV-1 isolates.
Our results indicate that the clinically relevant, macro- important chemotactic factor for dendritic cells (Sozzani
et al., 1995), which have been suggested to play anphage-tropic HIV-1 can use other members of the chem-
okine receptor family, such as CCR3 and CCR5, to facili- important role in HIV-1 transmission across mucosal
barriers (Spira et al., 1996). The expression of CCR3 ontate infection.
Although the tissue and cell-type distribution of CCR3 these and other potential HIV-1 target cells merits further
investigation.and CCR5 is not completely characterized, current data
are consistent with the hypothesis that these molecules The expression of CCR3 significantly enhanced infec-
tion by a smaller subset of primary HIV-1 than did CCR5contribute to in vivo infection by macrophage-tropic pri-
mary HIV-1 variants. The tissue distribution of CCR5 has expression. Although infection mediated by several of
the primary HIV-1 envelope glycoproteins was not de-beenreported tobe restricted to KG-1Apromyeloblastic
cells (Samson et al., 1996), but more recent data suggest tectably affected by CCR3 expression, significant CCR3
effects were observed for the YU2 and ADA envelopethat it is expressed in both CD4-positive and CD8-posi-
tive human PBMC, as well as in cells of the myeloid glycoproteins. This result suggests that heterogeneity
in chemokine receptor utilization may occur even amonglineage (C. G., unpublished data and Raport et al., 1996).
The latter distribution is consistent with that expected macrophage-tropic primary HIV-1 isolates. It is perhaps
relevant that, while all primary HIV-1 isolates are morebased upon the known host cell range of primary HIV-1
isolates. The expression of CCR3 appears to be more resistant to antibody neutralization than are laboratory-
adapted viruses (Montefiori et al., 1991; Bou-Habib etrestricted, with high levels of expression in eosinophils
and little expression in peripheral blood T lymphocytes al., 1994; Burton et al., 1994; Mascola et al., 1994; Moore
b-Chemokine Receptors as Entry Cofactors for HIV-1
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et al., 1995; Sullivan et al., 1995; Wrin et al., 1995; Karls- simplest model for post-CD4 binding events in HIV-1
entry would involve a direct interaction between the viralson et al., 1996), infection by the ADA and YU2 viruses
is actually enhanced by neutralizing antibodies (Sullivan envelope glycoproteins and the chemokine receptors.
The variability of gp120 tropism determinants, in particu-et al., 1995). It is unknown whether antibody-mediated
enhancement is related to utilization of CCR3, but the lar the V3 loop, among HIV-1 strains contrasts with the
minimal polymorphism observed in particular chemo-magnitude of both antibody and CCR3 enhancement
was greatest on viruses containing the YU2 envelope kine receptors. Our data indicate that infection by geo-
graphically and phylogenetically diverse HIV-1 isolatesglycoproteins. These observations raise the possibility
that a subset of primary HIV-1 exhibits previously unsus- can be facilitated by the same CCR5 molecule. If direct
envelope glycoprotein-chemokine receptor interactionpected properties allowing continued replication in par-
ticular cell types in the presence of neutralizing antibod- occurs, it may involve conserved structures on the
gp120 variable loops not apparent from inspection ofies. The YU2 sequences were directly cloned into phage
vectors from the central nervous system of an infected primary amino acid sequences. This situation may be
analogous to the binding of apparently diverse chemo-patient, thus avoiding even minimal passage on PBMC
(Li et al., 1991). Isolation of HIV-1 on peripheral blood T kines by the same chemokine receptor. Alternatively,
conserved envelope glycoprotein structures influencedlymphocytes, which do not express CCR3, in the ab-
sence of neutralizing antibodies may remove selection indirectly by variable loop configurations may directly
interact with the chemokine receptors. While CCR3 andpressure for viruses that can utilize these molecules to
CCR5 are closely related among the chemokine recep-enhance infection. Establishment of different in vitro
tors (Daugherty et al., 1996; Ponath et al., 1996b; Raportculture systems may allow the identification of addi-
et al., 1996; Samson et al., 1996), the relationship oftional HIV-1 isolates that can efficiently utilize CCR3.
either of these molecules to CCR1, which did not affectThe contribution of CCR3 to primary HIV-1 infection of
HIV-1 infection in our hands, is even greater. Again,different target cells in vivo and the relationship between
simple inspection of primary sequences does not revealCCR3 use and resistance to neutralizing antibodies will
determinants unique to CCR3 and CCR5 that might bebe evaluated in future studies.
targets for HIV-1 interaction. An alternative model is thatThe involvement of receptors for the b chemokines in
the chemokine receptors affect the target membraneHIV-1 infection explains the sensitivity of macrophage-
and/or CD4 in ways conducive to entry by viruses withtropic primary HIV-1 isolates, but not laboratory-
particular envelope glycoprotein configurations, withoutadapted isolates, to inhibition by RANTES, MIP-1a, and
directly contacting viral components. It is also possibleMIP-1b (Cocchi et al., 1995). Both CCR3 and CCR5 have
that G protein–mediated signaling plays a role in HIV-1been shown to be responsive to RANTES (Daugherty et
infection. Additional studies should distinguish amongal., 1996; Ponath et al., 1996b; Samson et al., 1996). The
these possibilities.increased HIV-1 inhibitory activity of RANTES compared
The involvement of G protein–coupled receptors inwith MIP-1a and MIP-1b suggests that CCR5 may not
two other instances of infection with pathogens hasbe solely responsible for mediating this inhibition, since
been reported. The Duffy antigen receptor, which bindsCCR5 has been reported to exhibit greater sensitivity
both a and b chemokines, facilitates invasion by theto MIP-1a than to RANTES (Samson et al., 1996). The
malarial parasite, Plasmodium vivax (Chaudhuri et al.,involvement of another chemokine receptor, such as
1993; Horuk et al., 1993). Similarly, the progression fromCCR3, which is responsive to RANTES but not to MIP-
colonization to infection with Streptococcus pneumon-1a or MIP-1b, in the HIV-1 inhibitory effect could explain
iae is facilitated by expression of the platelet-activatingthe data. Our data on eotaxin inhibition of CCR3-medi-
factor receptor (Cundell et al., 1995).ated HIV-1 infection suggest that suppression of virus
The b-chemokine receptors identified here may repre-infection may be a general consequence of ligand bind-
sent important host components that specify suscepti-ing to chemokine receptors that are specifically used
bility to HIV-1 infection or, inalready infected individuals,by particular HIV-1 strains. The mechanism by which
determine viral burden and rate of disease progression.chemokines exert their inhibitory effects on HIV-1 entry
Endogenous levels of RANTES, MIP-1a, and MIP-1bmaybe complex, involving receptorblockade, desensiti-
expression in CD4-positive lymphocytes were higherzation, sequestration or internalization, phosphoryla-
in some individuals that remained uninfected despitetion, or change in affinity state through G-protein uncou-
multiple sexual exposures to HIV-1 infected partnerspling (von Zastrow and Kobilka, 1992; Barak et al., 1994).
(Paxton et al., 1996). Additional contributions to patho-Further work will be required to distinguish among these
genic processes may occur as a result of inappropriatepossibilities.
signaling events triggered by direct interaction betweenThe ability of CCR3 and CCR5 to enhance both syncy-
viral components and the b-chemokine receptors. A bet-tium formation and the early phase of HIV-1 infection
ter understanding of the interaction of HIV-1, b chemo-suggests that these molecules facilitate virus binding to
kines, and their receptors may clarify the contributionthe target cell and/or membrane fusion. The structure
of these elements to virus transmission and pathogenicof the gp120 V3 loop, previously shown to specify target
outcome and may suggest approaches for intervention.cell–dependent membrane fusion efficiency (Cheng-
Mayer et al., 1990; O’Brien et al., 1990; Hwang et al.,
Experimental Procedures1991; Ivanoff et al., 1991; Westervelt et al., 1991, 1992;
Bergeron et al., 1992; Chesebro et al., 1992), determined Plasmids
the ability of the viral envelope glycoproteins to utilize The pHXBH10DenvCAT and pSVIIIenv plasmids used to produce
recombinant HIV-1 virions have been previously described (HelsethCCR3 and CCR5 as accessory factors for entry. The
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et al., 1990; Thali et al., 1994). The pCD4 plasmid expressing full- For some of the experiments, the level of chemokine receptor
expression on the transfected HeLa cells was measured by FACSlength human CD4 has been described (Brand et al., 1995). The SV-
A-MLV-Env plasmid expressing the amphotropic murine leukemia analysis 60 hr following transfection. The antibody (anti-FLAG M2,
Kodak) against the epitope tag (FLAG tag) was used for analysisvirus envelope glycoproteins was obtained from Dr. Dan Littman
(Landau et al., 1991). The derivation and construction of the pSVIII- of CCR1F, CCR3F, CCR4F, and CCR5F expression. Monoclonal
antibodies were used to detect surface expression of CCR2, PAF-env plasmids expressing the envelope glycoproteins from various
strains of HIV-1 have been described (Sullivan et al., 1995; Gao et RF, IL8RA, and IL8RB.
In some of the experiments, Cf2Th canine thymocytes were usedal., 1996; Karlsson et al., 1996). The chimeric HXBc2 (YU2-V3) and
HXBc2 (ADA-V3) env constructs were kindly supplied by Lee Ratner, as target cells. The Cf2Th cells were transfected by the calcium
phosphate technique with 10 mg of the pCD4 plasmid and 25 mg ofand were designated HY (V3A 1 V3B) and HA (V3A 1 V3B) in a
previouspublication (Carrillo et al., 1993). The chimeric HXBc2 (YU2- the pcDNA3 plasmid expressing chemokine receptors or, as a con-
trol, with 10 mg of the pCD4 plasmid and 25 mg of the pCDM8V1/V2) env genes were created by substituting the DraIII to StuI
fragment of the YU2 env gene into the corresponding segment (nu- plasmid expressing CD2 (see above). Approximately 72 hr after
transfection, the Cf2Th cells were incubated with recombinant HIV-1cleotides 6619–6901) of the HXBc2 env gene.
The cDNAs encoding the chemokine receptors were cloned into and used for measurement of CAT activity as described above.
the pcDNA3 vector (Invitrogen) for expression. Full-length cDNAs
for CCR1 (Neote et al., 1993), CCR2A and CCR2B (Charo et al., Eotaxin Inhibition of HIV-1 Infectivity
1994), CCR3 (Daugherty et al., 1996; Ponath et al., 1996b), CCR4 Eotaxin was chemically synthesized by Dr. Ian Clark-Lewis and puri-
(Power et al., 1995), and CCR5 (Samson et al., 1996) were cloned fied by high-pressure liquid chromatography after renaturation (Po-
by polymerase chain reaction, sequenced and shown to encode nath et al., 1996a). Recombinant HIV-1 containing the YU2 and
receptors capable of binding ligands following transfection. CCR1 A-MuLV envelope glycoproteins were produced in HeLa cells as
was shown to bind MIP-1a, RANTES, and MCP-3; CCR2 bound described above. HeLa-CD4 (clone 1022) cells, transfected either
MCP-1 and MCP-3; CCR3 bound eotaxin, RANTES, and MCP-3; with the pCDM8 plasmid expressing CD2 or with the pcDNA3 plas-
and CCR5 bound MIP-1a, MIP-1b, and RANTES. Plasmids encoding mid expressing chemokine receptors, were used as target cells.
IL8RA, IL8RB, PAF-RF, FMLP-RF, and C5aR were previously de- The target cells, in 1 ml medium, were incubated with different
scribed by the Gerard laboratory (Kunz et al., 1991; Gerard and concentrations (0–60 nM) of eotaxin for 90 min at 378C. Medium
Gerard, 1994). The HUMSTSR and Duffy antigen cDNAs were gener- was then removed and the cells were resuspended in 1 ml medium
ously provided by Dr. Kuldeep Neote. The EBI-1 expressor plasmid containing recombinant virus (15,000 reverse transcriptase units).
(Birkenbach et al., 1993) was obtained from Dr. Elliott Kieff. Eotaxin was added to the virus–cell mixture at the original concen-
The CCR1, CCR3, CCR4, and CCR5 proteins were also expressed tration. After 12 hr at 378C, the cells were washed and returned to
as fusion proteins containing an epitope tag (MDYKDDDDK) (FLAG the incubator. After an additional 48 hr at 378C, the cells were lysed
tag, IBI-Kodak) at the amino terminus. These fusion proteins are and used for measurement of CAT activity.
referred to as CCR1F, CCR3F, CCR4F, andCCR5F, respectively.The
platelet activating factor receptor and the f-Met-Leu-Phe receptor
Syncytium Formation Assaycontain the identical amino-terminal epitope tag, and are referred
Envelope glycoprotein-expressing HeLa cells were derived by co-to as PAF-RF and FMLP-RF, respectively.
transfection of HeLa cells with pSVIIIenv plasmids expressing HIV-1
envelope glycoproteins and a plasmid encoding the HIV-1 Tat pro-Cell Lines
tein (Helseth et al., 1990). Target cells were derived by transfectionHeLa cells were grown in Dulbecco’s modified Eagle’s medium con-
of HeLa-CD4 (clone 1022) cells with plasmids expressing eithertaining 10% fetal bovine serum and antibiotics. HeLa-CD4 (clone
CCR1, CCR3, or CCR5. The envelope glycoprotein-expressing and1022) cells were obtained from Dr. Bruce Chesebro through the
target HeLa cells were detached, 48 hr after transfection, from theNational Institutes of Health AIDS Research and Reference Reagent
tissue culture plates using 5 mM EDTA. Cells were replated at aProgram. The Cf2Th canine thymocyte line was obtained from the
ratio of ten target cells to one envelope glycoprotein-expressingAmerican Type Culture Collection (ATCC CRL 1430) and was propa-
cell and incubated at 378C in 5% CO2. The number of syncytia ingated in Dulbecco’s modified Eagle’s medium containing 10% fetal
the wells was counted 12 hr later. Control experiments were per-bovine serum.
formed in which 2 mg/ml OKT4a (Ortho Pharmaceuticals, Inc.) was
included at the time of replating. An additional control using theEnv-Complementation Assay
pCEP4 plasmid (Invitrogen), which does not express any envelopeHeLa cells were cotransfected by the calcium phosphate method
glycoproteins, was performed to assess background levels of syn-(Cullen, 1989) either with 15 mg pHXBH10DenvCAT alone or with
cytia.15mg pHXBH10DenvCAT and 3 mg pSVIIIenv or SV-A-MLV-Env to
produce recombinant virions, as previously described (Thali et al.,
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